TLDR
- VNRX surges as Capture-Seqâ„¢ detects 93% of cancers with 95% specificity.
- VolitionRx blood test catches 94% of Stage I cancers, sending VNRX soaring.
- VNRX eyes $36B market after landmark multi-cancer early detection breakthrough.
- VolitionRx’s Capture-Seqâ„¢ outperforms rivals, fueling VNRX licensing deal talks.
- VNRX stock spikes as blood test hits 93% sensitivity across all cancer stages.
VolitionRx Limited (VNRX) stock surged nearly 50% on Wednesday morning. VNRX opened near $0.20 and spiked to a high of $0.29 at market open. The rally followed a major announcement on its Capture-Seqâ„¢ cancer detection technology.
Capture-Seqâ„¢ Delivers Strong Blinded Validation Results
VNRX released blinded validation data from a cohort of 81 subjects. The study included 59 cancer patients and 22 healthy controls across colorectal and lung cancer cases. Results showed an overall sensitivity of 93% and specificity of 95%.
The technology detected Stage I cancer in 94% of cases and Stage II in 96%. Moreover, Stage III showed a perfect 100% detection rate across tested subjects. These figures position VNRX as a strong contender in the multi-cancer early detection space.
Capture-Seqâ„¢ works by enriching plasma samples to isolate circulating tumor DNA. The process produces virtually pure ctDNA for analysis, improving detection accuracy significantly. Furthermore, VNRX filed multiple new patents to protect this proprietary technology.
Early-Stage Cancer Detection Drives Commercial Interest
VNRX sees a major commercial opportunity in its Capture-Seqâ„¢ platform. The company estimates a total addressable market of approximately $23 billion for human multi-cancer early detection use. Additionally, the minimal residual disease segment presents a market opportunity exceeding $13 billion.
The company is currently in active discussions with several large liquid biopsy and diagnostic companies. These talks aim to accelerate the development and commercial launch of Capture-Seq™. VNRX believes this technology fits well within its existing Nu.Q® product portfolio.
The announcement generated strong interest from potential licensing partners across the diagnostics industry. VNRX also sees applications in veterinary medicine alongside human healthcare markets. Both sectors represent significant long-term revenue streams for the company.
VNRX Background and Market Position
VNRX is a multi-national epigenetics company focused on liquid biopsy diagnostics. The company has built its platform around circulating cell-free nucleoproteins, a differentiated scientific approach. VNRX believes it is the first liquid biopsy company to focus on this biological target.
VNRX stock pulled back to $0.1967 by early afternoon. The stock gave back most of its intraday gains as trading volume normalized. VNRX remains in focus given the clinical and commercial significance of its latest data.
The broader diagnostics sector continues to grow rapidly, and VNRX aims to capture a meaningful share. Early detection tools like Capture-Seqâ„¢ address an unmet clinical need globally. VNRX now moves toward larger cohort validation to support regulatory and commercial progress.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
